Literature DB >> 1309005

The platelet-activating factor acetylhydrolase from human plasma prevents oxidative modification of low-density lipoprotein.

D M Stafforini1, G A Zimmerman, T M McIntyre, S M Prescott.   

Abstract

Entities:  

Mesh：

Substances：

Year:  1992        PMID： 1309005

Source DB:  PubMed          Journal:  Trans Assoc Am Physicians        ISSN： 0066-9458


× No keyword cloud information.
  18 in total

1.  Association of a G994 -->T missense mutation in the plasma platelet-activating factor acetylhydrolase gene with risk of abdominal aortic aneurysm in Japanese.

Authors:  Naoki Unno; Toshio Nakamura; Hiroshi Mitsuoka; Takashi Uchiyama; Naoto Yamamoto; Takaaki Saito; Junko Sugatani; Masao Miwa; Satoshi Nakamura
Journal:  Ann Surg       Date:  2002-02       Impact factor: 12.969

2.  Protective effect of high density lipoprotein associated paraoxonase. Inhibition of the biological activity of minimally oxidized low density lipoprotein.

Authors:  A D Watson; J A Berliner; S Y Hama; B N La Du; K F Faull; A M Fogelman; M Navab
Journal:  J Clin Invest       Date:  1995-12       Impact factor: 14.808

Review 3.  Lipoprotein-associated phospholipase A2 prognostic role in atherosclerotic complications.

Authors:  Giuseppe Maiolino; Valeria Bisogni; Giacomo Rossitto; Gian Paolo Rossi
Journal:  World J Cardiol       Date:  2015-10-26

4.  Mildly oxidized LDL induces an increased apolipoprotein J/paraoxonase ratio.

Authors:  M Navab; S Hama-Levy; B J Van Lenten; G C Fonarow; C J Cardinez; L W Castellani; M L Brennan; A J Lusis; A M Fogelman; B N La Du
Journal:  J Clin Invest       Date:  1997-04-15       Impact factor: 14.808

5.  Overexpression of apolipoprotein AII in transgenic mice converts high density lipoproteins to proinflammatory particles.

Authors:  L W Castellani; M Navab; B J Van Lenten; C C Hedrick; S Y Hama; A M Goto; A M Fogelman; A J Lusis
Journal:  J Clin Invest       Date:  1997-07-15       Impact factor: 14.808

6.  Oxidatively modified LDL contains phospholipids with platelet-activating factor-like activity and stimulates the growth of smooth muscle cells.

Authors:  J M Heery; M Kozak; D M Stafforini; D A Jones; G A Zimmerman; T M McIntyre; S M Prescott
Journal:  J Clin Invest       Date:  1995-11       Impact factor: 14.808

7.  A simple and precise method for the routine determination of platelet-activating factor in blood and urine.

Authors:  C A Demopoulos; N K Andrikopoulos; S Antonopoulou
Journal:  Lipids       Date:  1994-04       Impact factor: 1.880

8.  Functional impairment of two novel mutations detected in lipoprotein-associated phospholipase A2 (Lp-PLA2) deficiency patients.

Authors:  Mitsuaki Ishihara; Tadao Iwasaki; Makoto Nagano; Jun Ishii; Mayumi Takano; Takeshi Kujiraoka; Masahiro Tsuji; Hiroaki Hattori; Mitsuru Emi
Journal:  J Hum Genet       Date:  2004-05-18       Impact factor: 3.172

9.  Characterization of the platelet-activating factor acetylhydrolase from human plasma by heterologous expression in Xenopus laevis oocytes.

Authors:  Y Yamada; D M Stafforini; T Imaizumi; G A Zimmerman; T M McIntyre; S M Prescott
Journal:  Proc Natl Acad Sci U S A       Date:  1994-10-25       Impact factor: 11.205

10.  Studies on HDL associated enzymes under experimental hypercholesterolemia: possible modulation on selenium supplementation.

Authors:  Harman D Kaur; Mohinder P Bansal
Journal:  Lipids Health Dis       Date:  2009-12-16       Impact factor: 3.876
View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.